DMT Analogue

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its novel DMT-based synthetic compound. Conducted at Hammersmith Medicines Research Ltd. in the U.K.,...

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin a Phase 1 clinical trial in 2022’s fourth quarter. The decision to focus research on...